Introduction
============

Post-thrombotic syndrome is a common and chronic complication of deep venous thrombosis of the leg that may develop in one of every two to three patients despite optimal anticoagulant treatment.[@ref1] [@ref2] Most patients with post-thrombotic syndrome develop the first symptoms within two years after diagnosis of deep venous thrombosis, the majority within the first year.[@ref3] [@ref4] [@ref5] [@ref6] Symptoms of post-thrombotic syndrome may range from skin changes through pain or mild swelling to badly controlled oedema and chronic leg ulcers, often needing high intensity medical treatment. Patients with post-thrombotic syndrome also report significant disability and impaired quality of life, which imposes a considerable economic burden on patients and healthcare systems.[@ref2] [@ref7] [@ref8] [@ref9]

Strategies for prevention of post-thrombotic syndrome involve use of thromboprophylaxis in patients at significant risk for deep venous thrombosis and providing anticoagulation of appropriate intensity and duration once it is established.[@ref2] In addition, the results of two relatively small randomised controlled trials have suggested that continuous use of graded elastic compression stockings (ECS) for at least two years provides a 50% reduction in the incidence of post-thrombotic syndrome compared with no stockings, with a number needed to treat of four patients.[@ref4] [@ref6] This strategy has been implemented in international guidelines and daily clinical practice. The effectiveness of ECS in preventing post-thrombotic syndrome is debated, however, as a placebo effect in the trials cannot be excluded. The positive effect of ECS was recently challenged by the SOX trial, which could not show any benefit of ECS over placebo stockings in the prevention of post-thrombotic syndrome.[@ref10] Notably, this trial had very poor adherence; only 56% of patients were using the study stockings for three days a week or more at the end of the study, and a clear trend to less frequent use of the stocking was apparent over the two year follow-up period. The SOX trial strongly underlined the major problem of non-adherence, probably due to local irritation and cosmetic reasons.[@ref11]

Pragmatic considerations have led to the suggestion to discontinue compression therapy earlier, although evidence supporting this practice is lacking. Both incidence of post-thrombotic syndrome and adherence to ECS decrease over time.[@ref4] [@ref6] [@ref10] A prospective management cohort study with 125 participants in Maastricht, the Netherlands, suggested that individually tailored duration of ECS based on Villalta scores and ultrasound findings can be effective and shorten duration of ECS use.[@ref12] This strategy is being studied in a randomised clinical trial.[@ref13] We hypothesised that ECS therapy for 12 months would be non-inferior to prevention of post-thrombotic syndrome with standard care---that is, ECS therapy for 24 months. Accordingly, the aim of our study was to evaluate the effect of ECS therapy for a period of 12 months versus 24 months after a diagnosis of proximal deep venous thrombosis on the occurrence of post-thrombotic syndrome and disease specific quality of life.

Methods
=======

Study patients
--------------

The study was conducted in eight teaching hospitals in the Netherlands, including one university medical centre. Between February 2009 and September 2013, consecutive patients in the outpatient clinic with a recent diagnosis of deep venous thrombosis were invited to participate in this trial. Patients were eligible for inclusion if they had been diagnosed as having a symptomatic, compression ultrasound proven, proximal deep venous thrombosis of the leg (popliteal or more proximal deep leg veins) less than one year previously; had been treated with anticoagulants in accordance with applicable guidelines; had received graduated ECS class III (34-46 mm Hg); and reported strict compliance, defined as using the stockings at least six days a week. Exclusion criteria were recurrent ipsilateral deep venous thrombosis; calf vein thrombosis (defined as thrombosis only below the level of the popliteal vein); post-thrombotic syndrome diagnosed in the first year after deep venous thrombosis before study inclusion, defined as a Villalta score of 5 points or more[@ref14] [@ref15] [@ref16]; use of ECS before the index deep venous thrombosis diagnosis for other reasons; a contraindication to wearing compression stockings, such as arterial insufficiency or allergy; life expectancy less than six months; comorbid conditions or geographical inaccessibility precluding return for follow-up visits; and no informed consent.

Randomisation and blinding
--------------------------

One year after diagnosis of the index deep venous thrombosis, all eligible patients visited the outpatient clinic for definite screening of inclusion and exclusion criteria, baseline visit, and randomisation. Randomisation used an online randomisation module provided by the Dutch Julius Centre for Health Sciences and Primary Care in Utrecht, the Netherlands, which ensured concealed allocation. We used stratification for sex, study centre, and timing of randomisation per season of the year (to correct for possible seasonal differences in use of ECS). After randomisation, the study participants received a written alert with their allocation. Treatment allocation was masked from study personnel during follow-up. Patients who were allocated to standard care were asked not to wear the stocking on the day of follow-up, and all study participants were instructed not to reveal their allocation at study visits.

Procedures and outcome assessment
---------------------------------

Patients were randomly assigned to either continue or stop wearing active graduated ECS one year after the index deep venous thrombosis. Patients allocated to the stop-ECS group stopped using the ECS on the day they received the written alert of randomisation. ECS were used only during daytime hours, and no other specific form of calf muscle exercise (or instructions to do so) was performed. Follow-up visits were scheduled at three, six, and 12 months from the baseline visit (fig 1[](#f1){ref-type="fig"}). At baseline, a clinical history was taken detailing the presence of risk factors for venous thrombosis, the applied anticoagulation treatment, the first time of ECS use, adherence to ECS in the first year after diagnosis of deep venous thrombosis, medical history, and current use of (anticoagulant) drugs. The extent and location of the deep venous thrombosis were verified with the original compression ultrasound reports.

![**Fig 1** Study design (time in months). ECS=elastic compression stockings; VTE=venous thromboembolism](molg029206.f1_default){#f1}

The primary endpoint was the incidence of post-thrombotic syndrome at the end of the follow-up period---that is, post-thrombotic syndrome occurring in the second year after a diagnosis of deep venous thrombosis. Post-thrombotic syndrome was scored using the Villalta scale assessed with the aid of a full colour visual guide,[@ref10] [@ref15] with post-thrombotic syndrome defined as a score of 5 points or more or the presence of a venous ulcer.[@ref14] [@ref16] The Villalta scale was preferably evaluated in the afternoon by a maximum of two experienced outcome assessors for each participating centre. The presence of post-thrombotic syndrome was evaluated at the outpatient clinic during the baseline visit and after six and 12 months. At the three month visit, patients were contacted by telephone to evaluate them (using a checklist) for new signs of post-thrombotic syndrome. If any signs were present, the phone call was followed by clinical evaluation.

Secondary endpoints included adherence to ECS use during study follow-up as reported by the patients at the 12 month visit, recurrent deep venous thrombosis in the same leg as the index event, death, and within patient changes in quality of life over the study period as assessed by the VEINES-QOL/Sym questionnaire that was recorded at baseline and at the 12 month visit.[@ref17] [@ref18] The outcome of the VEINES-QOL/Sym questionnaire is reported in two dimensions---overall quality of life (VEINES-QOL; 25 items) and symptom severity (VEINES-Sym; 10 items). Both scales theoretically lie between 0 and 100 (visual analogue scale) with a higher score indicating a higher quality of life.[@ref18] [@ref19] [@ref20] We defined dedicated ECS use as use of the ECS for at least six days a week, moderate use as four to five days a week, and poor use less than four days a week. We defined recurrent ipsilateral deep venous thrombosis as a new non-compressible venous segment compared with the original compression ultrasound images of the index deep venous thrombosis or a pronounced increase in vein diameter on compression.[@ref21] [@ref22] [@ref23]

Statistical analysis
--------------------

The trial was designed to determine whether 12 months of ECS use was non-inferior to 24 months, with a predefined non-inferiority margin of 10%, meaning that the upper boundary of the 95% confidence interval of the absolute difference between the primary endpoint in the two study groups would be lower than 10%. We agreed on this margin as a clinically relevant maximum increase in diagnoses of post-thrombotic syndrome that would be acceptable to change the current recommendation of ECS duration from 24 to 12 months. We analysed efficacy according to an intention to treat principle to assess the incidence of post-thrombotic syndrome. We determined the sample size on the basis of an expected rate of the primary efficacy outcome in the reference group (continue-ECS group) of 2-3%, derived from cohorts in previous studies, in which the incidence of post-thrombotic syndrome in the second year after deep venous thrombosis was about that percentage,[@ref4] [@ref6] and the requirement to achieve 80% power to detect the predefined non-inferiority margin at a one sided α level of 0.05. Assuming a loss to follow-up of 10%, including deaths and recurrent ipsilateral deep venous thrombosis events, the total study population was set at 516 people.

We additionally did a per protocol analysis of the primary endpoint. We then did extended Cox regression analyses on the primary outcome with adjustment for adherence and baseline covariates---that is, age, sex, body mass index, unprovoked or secondary deep venous thrombosis, extent of the index deep venous thrombosis, baseline Villalta score, study site, and the use of oral anticoagulants during the study period.

For secondary endpoints, we compared the occurrence of recurrent ipsilateral deep venous thrombosis and overall mortality between the two study cohorts by using a Cox proportional hazard model, adjusted for age, sex, unprovoked or secondary deep venous thrombosis, study site, and the use of oral anticoagulants during the study period. Finally, we applied an independent samples *t* test to compare within patient changes in quality of life scores from baseline to time of last follow-up and a Mann-Whitney U test to compare quality of life between the two patient groups at the end of follow-up.

After locking the database, we noted that 28% of patients had been incorrectly treated with 23-32 mm Hg graduated active stockings instead of the intended ECS class of 34-46 mm Hg. To correct for this potential confounder, we calculated the effect of ECS class on the primary endpoint and additionally repeated all secondary analyses with adjustment for ECS class.

We used SPSS statistics 22.0 for all statistical analyses. P values below 0.05 were considered statistically significant.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the study. No patients were asked to advise on interpretation or writing up of results. The results of the research will be disseminated to the relevant patient community after publication.

Results
=======

Patients
--------

Figure 2[](#f2){ref-type="fig"} shows the flow chart of the study, mapping the inclusion and progress of participants. Of 3603 eligible patients, 1110 declined to participate and 1971 were excluded. Reasons for exclusion were previous deep venous thrombosis in the same leg as the index event (n=530), calf vein thrombosis only (n=527), other indication for use of compression stockings (n=140), or post-thrombotic syndrome diagnosed in the first year after deep venous thrombosis (n=93). Furthermore, 56 patients had an expected lifespan of less than six months, 293 died in the first year after deep venous thrombosis before randomisation, and 332 had serious comorbid conditions or were geographically inaccessible precluding follow-up. Finally, four ineligible patients were incorrectly randomised (one patient diagnosed as having post-thrombotic syndrome at baseline and three patients who did not use ECS at the time of randomisation) and were excluded, leaving 518 patients for the primary analysis, of whom 256 were allocated to the group who stopped using ECS and 262 to the group who continued use of ECS. Baseline characteristics were comparable between the two groups with regard to age, sex, previous history of venous thromboembolism, cause of index deep venous thrombosis, mean duration of anticoagulation, number of patients on active anticoagulant treatment at randomisation, and frequency of ECS use at baseline (table 1[](#tbl1){ref-type="table"}).

![**Fig 2** Flow chart of study. DVT=deep venous thrombosis; ECS=elastic compression stockings; PTS=post-thrombotic syndrome](molg029206.f2_default){#f2}

###### 

Baseline characteristics. Values are numbers (percentages) unless stated otherwise

  Characteristics                                                               Stop-ECS (n=256)   Continue-ECS (n=262)
  ----------------------------------------------------------------------------- ------------------ ----------------------
  Mean (SD) age, years                                                          57 (14)            56 (14)
  Male sex                                                                      152 (59)           155 (59)
  Mean (SD) body mass index                                                     28 (4.8)           28 (4.5)
  Median (IQR) duration of complaints before diagnosis of DVT, days             5 (2-14)           5 (2-14)
  History of venous thromboembolism                                             37 (15)            38 (15)
  Provoked index DVT                                                            142 (56)           161 (62)
   Trauma \<8 weeks                                                             57 (22)            61 (23)
   Surgery (general anaesthesia) \<8 weeks                                      32 (13)            33 (13)
   Prolonged immobilisation \>6 days                                            26 (10)            22 (8)
   Pregnant, postpartum, hormonal replacement therapy                           55 (22)            64 (24)
   Cancer active at diagnosis                                                   29 (11)            21 (8)
   Known thrombophilia\*                                                        17 (7)             24 (9)
  History of varicose veins                                                     36 (14)            29 (11)
  Current or former smoking                                                     67 (26)            68 (26)
  Index DVT in left leg                                                         158 (62)           144 (55)
  Most proximal location of DVT:                                                                   
   Iliac vein                                                                   23 (9)             25 (10)
   Communal femoral vein                                                        44 (17)            31 (12)
   Superficial femoral vein                                                     58 (23)            54 (21)
   Popliteal vein                                                               131 (51)           152 (58)
  Treatment of DVT:                                                                                
   Median (IQR) duration of LMWH or heparin in patients switched to VKA, days   10 (7-21)          12 (7-21)
   Median (IQR) duration of VKA treatment, months                               6 (4-6)            6 (4.5-6)
  Active anticoagulant treatment at randomisation                               39 (15)            37 (14)
  Frequent users of ECS at baseline (≥6 days/week)                              232 (91)           249 (95)
  Mean (SD) baseline Villalta score                                             1.9 (1.3)          1.8 (1.3)

DVT=deep venous thrombosis; ECS=elastic compression stockings; IQR=interquartile range; LMWH=low molecular weight heparin; SD=standard deviation; VKA=vitamin K antagonist.

\*Antithrombin, protein C or S deficiency, factor V Leiden or prothrombin mutation, presence of antiphospholipid antibodies.

Study flow
----------

During the study period, 12 patients were lost to follow-up (six (2.3%) in the stop-ECS group and six (2.3%) in the continue-ECS group) and 19 patients withdrew informed consent (13 (5.1%) *v* 6 (2.3%) (fig 2[](#f2){ref-type="fig"}). The 12 patients lost to follow-up included two patients who moved out of the area (one patient in each group). Of the 19 patients who withdrew consent, 13 failed to comply with the treatment allocation: two patients did not want to stop using ECS after being randomised to the stop-ECS group, six started using ECS during the follow-up despite being allocated to stop wearing ECS, and five from the continue-ECS group stopped using ECS during the follow-up. Thus, 518 patients (256 in the stop-ECS group and 262 in the continue-ECS group) were available for the primary efficacy analysis.

Primary endpoint
----------------

At the 12 month follow-up, data on adherence to ECS was available for 218 patients in the continue-ECS group. In this group, 186 (85%) patients reported use of ECS six to seven days a week, 15 (7%) reported use four to five days a week, and 17 (8%) reported use less than four days a week. In the stop-ECS group, 51 patients developed post-thrombotic syndrome compared with 34 patients in the continue-ECS group. The incidence of post-thrombotic syndrome in the second year after deep venous thrombosis was 19.9% (95% confidence interval 16% to 24%) in the stop-ECS group and 13.0% (9.9% to 17%) in the continue-ECS group, for an absolute difference of 6.9% (95% confidence interval upper limit 12.3%) (table 2[](#tbl2){ref-type="table"}). Hence, we did not meet our predefined criterion for non-inferiority, as the upper 95% confidence limit of the absolute difference in the incidence of post-thrombotic syndrome exceeded the 10% non-inferiority limit (as shown in figure 3[](#f3){ref-type="fig"}).

###### 

Primary and secondary endpoints by treatment group

                                                           Stop-ECS group (n=256)   Continue-ECS group (n=262)   Adjusted hazard ratio (95% CI)/P value
  -------------------------------------------------------- ------------------------ ---------------------------- ----------------------------------------
  **Primary endpoint**                                                                                           
  PTS incidence, % (95% CI)                                19.9 (16 to 24)          13.0 (9.9 to 17)             1.6 (1.02 to 2.5)\*
  Absolute No (%) of mild PTS (Villalta scale 5-9)         43 (84)                  31 (91)                      --
  Absolute No (%) of moderate PTS (Villalta scale 10-14)   8 (16)                   2 (6)                        --
  Absolute No (%) of severe PTS (Villalta scale \>14)      0                        1 (3)                        --
  **Secondary endpoints**                                                                                        
  Incidence of overall mortality, % (95% CI)               0.78 (0.003 to 3.0)      0 (0 to 1.7)                 0.97 (NC)†
  Incidence of ipsilateral recurrent DVT, % (95% CI)       3.1 (1.5 to 6.2)         2.3 (0.94 to 5.0)            1.5 (0.54 to 4.2)‡
  Quality of life:                                                                                               
   Median (IQR) VEINES-QOL at end of follow-up             96 (92-98)               96 (90-99)                   P=0.99§
   Median (IQR) VEINES-SYM at end of follow-up             95 (88-100)              95 (88-100)                  P=0.99§
   Mean (95% CI) intra-individual change in VEINES-QOL     −0.15 (−1.5 to 1.2)      0.93 (−0.29 to 2.1)          P=0.21¶
   Mean (95% CI) intra-individual change in VEINES-Sym     −1.1 (−1.7 to 0.44)      0.58 (−0.90 to 2.1)          P=0.12¶

DVT=deep venous thrombosis; IQR=interquartile range; PTS=post-thrombotic syndrome.

\*Adjusted for age, sex, body mass index, unprovoked or secondary DVT, extent of index DVT, baseline Villalta score, and use of oral anticoagulants during study period.

†Not computable owing to 0 cases in continue-ECS group.

‡Adjusted for age, sex, unprovoked or secondary DVT, and use of oral anticoagulants during study period,

§Mann-Whitney U test.

¶Independent samples *t* test.

![**Fig 3** Treatment difference outcome with non-inferiority margin. DVT=deep venous thrombosis; ECS=elastic compression stockings](molg029206.f3_default){#f3}

The number needed to treat to prevent one case of post-thrombotic syndrome by continuing ECS was 14 (95% confidence interval lower limit 8). The median period between randomisation and occurrence of post-thrombotic syndrome was 4 (interquartile range 3-6) months in the stop-ECS group compared with 6 (3-12) months in the continue-ECS group (P=0.17 by Mann-Whitney U test). Of the 51 patients in the stop-ECS group who developed post-thrombotic syndrome, 43 (84%) were classified as mild (Villalta score 5-9), eight (16%) as moderate (Villalta score 10-14), and none as severe post-thrombotic syndrome (ulcer or Villalta score \>14) compared with 31 (91%), 2 (6%), and 1 (3%) in the continue-ECS group (P=0.19 by χ^2^ test) (table 2[](#tbl2){ref-type="table"}). The one patient with severe post-thrombotic syndrome was diagnosed as having a venous ulcer. The adjusted hazard ratio for development of post-thrombotic syndrome was 1.6 (95% confidence interval 1.02 to 2.5) to the disadvantage of patients in the stop-ECS group.

Secondary endpoints
-------------------

The per protocol analysis yielded similar results to the intention to treat analysis, with a incidence of post-thrombotic syndrome of 19.1% (15% to 24%) in the stop-ECS group and 12.0% (9% to 16%) in the continue-ECS group, for an absolute difference of 7.1% (95% confidence interval upper limit 13%). Again, this did not meet our predefined criterion for non-inferiority, as the upper 95% confidence limit for the absolute difference in the incidence of post-thrombotic syndrome was 13% in the per-protocol analysis, which is greater than the 10% upper limit for non-inferiority. The adjusted hazard ratio for development of post-thrombotic syndrome was 1.4 (0.86 to 2.0) to the disadvantage of patients in the stop-ECS group.

Fourteen patients developed recurrent ipsilateral deep venous thrombosis: eight (3.1%) in the stop-ECS group and six (2.3%) in the continue-ECS group (table 2[](#tbl2){ref-type="table"}). Two patients in the stop-ECS group died (incidence 0.78%), compared with none in the continue-ECS group. Causes of death were end stage pulmonary carcinoma (male, aged 73) and heart failure after myocardial infarction leading to asystole (female, aged 75).

At baseline, 253 (99%) of 256 patients in the stop-ECS group and 259 (99%) of 262 patients in the continue-ECS group completed the VEINES-QOL/Sym questionnaire, compared with 186 (81% of 230 available patients) and 212 (87% of 245 available patients) at the end of follow-up. In the stop-ECS group, VEINES-QOL and VEINES-Sym scores decreased non-significantly, whereas both improved slightly in the continue-ECS group during the follow-up period (table 2[](#tbl2){ref-type="table"}). We found no statistical differences between the two study groups with regards to the intra-individual changes in both dimensions, nor in the median quality of life at the end of follow-up.

ECS class was not associated with the occurrence of the primary endpoint (hazard ratio 0.93, 0.58 to 1.5). Adjustment for ECS class did not change the secondary endpoints, including quality of life.

Discussion
==========

Post-thrombotic complaints often occur in patients with proximal deep venous thrombosis. We have shown that after an episode of proximal deep venous thrombosis, stopping ECS therapy failed to meet the criterion for non-inferiority compared with the current recommended medical practice of continuing to wear stockings for a second year among patients who completed one year of compliant use of elastic compression stockings. We observed an absolute excess in diagnoses of post-thrombotic syndrome of 6.9 percentage points (95% confidence interval upper limit 12.3%) in the group that stopped using ECS after one year, although the mean severity of post-thrombotic syndrome did not differ between the two groups. Importantly, only 16% of patients in the stop-ECS group developed moderate or severe post-thrombotic syndrome in the second year. ECS did not affect the rate of recurrent ipsilateral deep venous thrombosis nor venous disease specific quality of life.

In the per protocol analysis, the difference between the active treatment and no ECS therapy was comparable, with the upper limit of the 95% confidence interval exceeding the non-inferiority limit of 10%.

Comparison with previous studies
--------------------------------

Our results seem to be in contrast to those of the recently published SOX trial showing that ECS did not prevent post-thrombotic syndrome after a first proximal deep venous thrombosis, although the primary endpoint in the studies was different precluding a direct comparison.[@ref10] In that study, 806 patients were randomised to wear active (30-40 mm Hg) versus placebo (\<5 mm Hg compression at the ankle) ECS for a two year period. The primary endpoint---cumulative incidence of post-thrombotic syndrome assessed by Ginsberg's criteria---was 14.2% for active ECS compared with 12.7% in the placebo ECS group, for a non-significant hazard ratio of 1.13 (95% confidence interval 0.73 to 1.76).[@ref10] The Villalta score was used as a secondary outcome measure in this study. The cumulative incidences of post-thrombotic syndrome measured by Villalta's criteria in that study were 52.6% and 52.3%, respectively. Notably, adherence in that study was much lower than in our study, with only 56% of patients wearing their stocking for at least three days a week at the end of the follow-up period. In contrast, 93% of the patients in our study reported use of ECS at least six days a week at baseline. At the end of follow-up in our continue-ECS group, 84% of patients reported using ECS six to seven days a week, and 94% of patients used the stockings for at least four days a week. The threshold for frequent ECS use of three days a week in the SOX trial may have been too lenient to detect an effect of ECS on development of post-thrombotic syndrome. Another difference between the two studies was that our study was not placebo controlled, which may also have contributed to the difference in study results, although we consider the factor of adherence to be more important.

Our results are in line with those of three other randomised controlled trials.[@ref4] [@ref6] [@ref24] Two single centre, open label studies randomised patients with proximal deep venous thrombosis to either daily use of ECS for at least two years or no stockings.[@ref4] [@ref6] Both studies reported a beneficial effect of ECS with an absolute reduction in the cumulative post-thrombotic syndrome incidence as measured with the Villalta or a Villalta-like scale of more than 20%. A third small trial randomised patients with deep venous thrombosis who had used ECS for six months to stopping stockings or using them for an additional 18 months.[@ref24] A non-significant reduction in post-thrombotic syndrome of 6.9 percentage points was observed in the patients allocated to continued ECS use. Notably, post-thrombotic syndrome in this study was assessed according to the CEAP classification, which combines clinical and objective findings but does not take symptoms into account, in contrast to Villalta's scale. Symptom relief, which was a secondary outcome of the study, was significantly in favour of active use of ECS during the first year but not thereafter.[@ref24] Self reported adherence to the therapy in all three studies was excellent, with more than 90% of patients wearing the stockings for at least six days a week. A limitation of all three studies is the lack of a double blind design. With this in mind, the number needed to treat increases from five in the first year to eight in the second year with a range from seven to 62.

Strengths and limitations of study
----------------------------------

Strengths of our study include its multicentre design, the high quality centralised randomisation procedure, the considerable sample size, the very good adherence to the allocated therapy and response rates for the quality of life questionnaires, the exclusion of patients with deep venous thrombosis limited to the distal veins, and the assessment of both post-thrombotic syndrome and quality of life at several time points during follow-up.

Some methodological considerations of our study require comment. Only patients who were committed to dedicated use of the stockings were included in our study. Also, patients who had already developed post-thrombotic syndrome in the first year after deep venous thrombosis were ineligible to participate. Therefore, the study conclusions cannot necessarily be generalised to all patients with proximal deep venous thrombosis. Even so, this specific design allowed us to study the "true" effect of ECS without confounding by increasingly diminishing adherence throughout the follow-up period. With our design, we achieved excellent adherence with only 7.3% of patients in the continue-ECS group using their stockings less than four days a week at the end of the study. Also, we did a single blinded randomised trial that was not controlled by a placebo intervention. A double blind placebo controlled study design would not have been viable because the nature of the intervention precluded effective blinding of patients through placebo stockings, as they all had 12 months' experience with active ECS. Although we used several strategies to reduce unmasking of treatment assignment to the observer who assessed the presence and severity of post-thrombotic syndrome, such as repeated strict instructions to the study participants not to reveal their allocation and not to wear the stocking on the day of follow-up, we cannot exclude bias caused by possible loss of blinding. Also, as use of stockings and some baseline variables such as "duration of symptoms" were reported by patients, recall bias may have been present. Furthermore, 28% of patients were treated with lower grade ECS than prescribed by the protocol. Even so, post hoc analyses did not show any interaction with ECS grade for either the primary or secondary endpoints, including quality of life. Moreover, it may be assumed that if the less effective than intended ECS treatment did alter our primary endpoint, our results represent an underestimation of the "true" therapeutic effect, which would underline our conclusion.

Another limitation of our study is that 19 (3.6%) patients withdrew their consent and 12 (2.3%) patients were lost to follow-up. This is below the estimated 10% in the power calculation and half the number reported in a recently published study in this field of research.[@ref10] Finally, we acknowledge that the rate of post-thrombotic syndrome in our study was higher than anticipated in the sample size considerations, which may have resulted in a lower power to prove our non-inferiority hypothesis.

Conclusions
-----------

We conclude that, in patients with a proximal deep venous thrombosis who are motivated to wear compression stockings, a strategy to stop ECS therapy after one year is not non-inferior to completing a two year period of ECS therapy, as the former is associated with an excess in diagnoses of post-thrombotic syndrome in the second year. Our results suggest that ECS affect the natural history of development of post-thrombotic syndrome after deep venous thrombosis. However, quality of life did not differ and only a few patients developed moderate or severe post-thrombotic syndrome in the second year in both study groups. On the basis of our results, we recommend continuing ECS therapy for 24 months after deep venous thrombosis. Of note, it may be hypothesised that prolonging ECS use after the 24 month period may be beneficial to selected patients to continuously prevent post-thrombotic syndrome development, as post-thrombotic changes are irreversible. Obviously, this will need to be tested in future trials.

### What is already known on this topic

1.  Elastic compression stockings (ECS) are used for the prevention of post-thrombotic syndrome after deep venous thrombosis, but the optimal duration of compression therapy is unknown

2.  Current guidelines suggest 24 months of ECS use, but recent studies have questioned this strategy with suggestions of shorter duration of ECS therapy

### What this study adds

1.  In patients with excellent adherence to ECS use, stopping ECS one year after deep venous thrombosis was not non-inferior to continuing ECS in preventing post-thrombotic syndrome

2.  ECS therapy should ideally be continued for 24 months after deep vein thrombosis
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